Sevikar is a fixed-dose combination of olmesartan and amlodipine: [12] Olmesartan is an angiotensin II receptor antagonist or blocker (ARB) which works by inhibiting the action of the RAS by (1) central blood pressure is believed to provide a more accurate reflection of the pressure experienced by the internal organs, (1) and there is an increasing amount of evidence from clinical studies to show that measures of central blood pressure predict damage to organs and the risk of disease- related events more accurately than brachial … PDF document [email protected] Marisa Tejedor Botello: Bachelor of Economics and Masters of Financial Management, has been a member of the Innovation Unit of FIBHULP since September 2010. Tel:912071740; e-mail: [email protected] María José Varela González: Law degree and Masters in Legal Practice, joined the Innovation Unit of FIBHULP in A simple, rapid, and selective HPLC-UV method was developed for the determination of antihypertensive drug substances: amlodipine besilat (AML), olmesartan medoxomil (OLM), valsartan (VAL), and hydrochlorothiazide (HCT) in pharmaceuticals and plasma. These substances are mostly used as combinations. The combinations are found in various forms, especially in current pharmaceuticals as threesome New clinical trial data, from the phase 4 Sevitension Study, will be presented at the 23rd European Meeting on Hypertension and Cardiovascular Protection (ESH) in Milan , comparing FDC treatment olmesartan and amlodipine with perindopril and amlodipine in reducing central aortic blood pressure.(6) Hypertension represents one of the most common and relevant cardiovascular (CV) risk factor (RF), accounting for more than 10 million deaths and 208 million Disability‐Adjusted Life Years. 1 Indeed, subjects affected by hypertension have a significantly increased risk of major CV events (MACE). SEVITENSION involved a 2- to 4-week open-label, run-in period that depended on patients' existing treatment at study entry. At weeks −4 to −2, patients not currently receiving AML as part of their antihypertensive treatment received AML 5 mg in addition to their current therapy, except for patients receiving other CCBs, which were discontinued. The EU Clinical Trials Register currently displays 42312 clinical trials with a EudraCT protocol, of which 6968 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006). Ruilope LM; SEVITENSION Study Investigators. Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016; 18:528-535. doi: 10.1111/jch.12673. Crossref Medline Google Scholar; 43. Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk 15.05.2014 - 13:10. Daiichi Sankyo Europe GmbH. World Hypertension Day 2014: Daiichi Sankyo "Makes Your Heart Feel Good!" with a pan-European charity initiative В иследовании sevitension участвовали пациенты, не достигшие контроля АД на фоне приема 10 мг амлодипина. Статья в формате pdf. Медична газета «Здоров'я України 21 сторіччя» № 8 (429), квітень 2018 р 15.05.2014 - 13:10. Daiichi Sankyo Europe GmbH. World Hypertension Day 2014: Daiichi Sankyo "Makes Your Heart Feel Good!